Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases

Journal of Clinical Oncology

Volumn 26, Issue 32, 2008, Pages 5254-5260

  Kesmodel, Susan B ^a   Ellis, Lee M ^a   Lin, E ^a   Chang, George J ^a   Abdalla, Eddie K ^a   Kopetz, Scott ^a   Vauthey, Jean Nicolas ^a   Rodriguez Bigas, Miguel A ^a   Curley, Steven A ^a   Feig, Barry W ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER PATIENT; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG WITHDRAWAL; FEMALE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; LIVER METASTASIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; SURGICAL RISK; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT RESPONSE; WOUND COMPLICATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 55949084563     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7857     Document Type: Article

References (30)

1. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
3. Saltz L, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
4. Allen PJ, Kemeny N, Jarnagin W, et al: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:109-115, 2003
5. Tanaka K, Adam R, Shimada H, et al: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90:963-969, 2003
6. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240:644-657, 2004
7. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
8. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
9. Donahower B, McCullough SS, Kurten R, et al: Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity. Am J Physiol Gastrointest Liver Physiol 291:G102-G109, 2006
10. Howdieshell TR, Callaway D, Webb WL, et al: Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96:173-182, 2001
11. Mochida S, Ishikawa K, Inao M, et al: Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. Biochem Biophys Res Commun 226:176-179, 1996
12. Redaelli CA, Semela D, Carrick FE, et al: Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 40:305-312, 2004
13. Taniguchi E, Sakisaka S, Matsuo K, et al: Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 49:121-130, 2001
14. Zhang F, Lei MP, Oswald TM, et al: The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds. Br J Plast Surg 56:334-341, 2003
15. Bilchik AJ, Poston G, Curley SA, et al: Neoadjuvant chemotherapy for metastatic colon cancer: A cautionary note. J Clin Oncol 23:9073-9078, 2005
16. Ellis LM, Curley SA, Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23:4853-4855, 2005
17. Couinaud C: Anatomic principles of left and right regulated hepatectomy: Technics. [in French] J Chir (Paris) 70:933-966, 1954
18. Martin RC, Jaques DP, Brennan MF, et al: Extended local resection for advanced gastric cancer: Increased survival versus increased morbidity. Ann Surg 236:159-165, 2002
19. Martin RC, Brennan MF, Jaques DP: Quality of complication reporting in the surgical literature. Ann Surg 235:803-813, 2002
20. Mullen JT, Ribero D, Reddy SK, et al: Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204:854-862, 2007
21. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061, 2004
22. Aloia T, Sebagh M, Plasse M, et al: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983-4990, 2006
23. Karoui M, Penna C, min-Hashem M, et al: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7, 2006
24. Kooby DA, Fong Y, Suriawinata A, et al: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034-1044, 2003
25. Kooby DA, Stockman J, Ben-Porat L, et al: Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 237:860-869, 2003
26. Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072, 2006
27. Scappaticci FA, Fehrenbacher L, Cartwright T, et al: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180, 2005
28. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
29. D'Angelica M, Kornprat P, Gonen M, et al: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 14:759-765, 2007
30. Reddy SK, Morse MA, Hurwitz HI, et al: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106, 2008